Solid state amide hydrogen/deuterium exchange with mass spectrometric analysis (ssHDX-MS) was used to assess the conformation of myoglobin (Mb) in lyophilized formulations, and the results correlated with the extent of aggregation during storage. Mb was colyophilized with sucrose (1:1 or 1:8 w/w), mannitol (1:1 w/w), or NaCl (1:1 w/w) or in the absence of excipients. Immediately after lyophilization, samples of each formulation were analyzed by ssHDX-MS and Fourier transform infrared spectroscopy (FTIR) to assess Mb conformation, and by dynamic light scattering (DLS) and size exclusion chromatography (SEC) to determine the extent of aggregation. The remaining samples were then placed on stability at 25 °C and 60% RH or 40 °C and 75% RH for up to 1 year, withdrawn at intervals, and analyzed for aggregate content by SEC and DLS. In ssHDX-MS of samples immediately after lyophilization (t = 0), Mb was less deuterated in solids containing sucrose (1:1 and 1:8 w/w) than in those containing mannitol (1:1 w/w), NaCl (1:1 w/w), or Mb alone. Deuterium uptake kinetics and peptide mass envelopes also indicated greater Mb structural perturbation in mannitol, NaCl, or Mb-alone samples at t = 0. The extent of deuterium incorporation and kinetic parameters related to rapidly and slowly exchanging amide pools (Nfast, Nslow), measured at t = 0, were highly correlated with the extent of aggregation on storage as measured by SEC. In contrast, the extent of aggregation was weakly correlated with FTIR band intensity and peak position measured at t = 0. The results support the use of ssHDX-MS as a formulation screening tool in developing lyophilized protein drug products.
Solid state amidehydrogen/deuterium exchange with mass spectrometric analysis (ssHDX-MS) was used to assess the conformation of myoglobin (Mb) in lyophilized formulations, and the results correlated with the extent of aggregation during storage. Mb was colyophilized with sucrose (1:1 or 1:8 w/w), mannitol (1:1 w/w), or NaCl (1:1 w/w) or in the absence of excipients. Immediately after lyophilization, samples of each formulation were analyzed by ssHDX-MS and Fourier transform infrared spectroscopy (FTIR) to assess Mb conformation, and by dynamic light scattering (DLS) and size exclusion chromatography (SEC) to determine the extent of aggregation. The remaining samples were then placed on stability at 25 °C and 60% RH or 40 °C and 75% RH for up to 1 year, withdrawn at intervals, and analyzed for aggregate content by SEC and DLS. In ssHDX-MS of samples immediately after lyophilization (t = 0), Mb was less deuterated in solids containing sucrose (1:1 and 1:8 w/w) than in those containing mannitol (1:1 w/w), NaCl (1:1 w/w), or Mb alone. Deuterium uptake kinetics and peptide mass envelopes also indicated greater Mb structural perturbation in mannitol, NaCl, or Mb-alone samples at t = 0. The extent of deuterium incorporation and kinetic parameters related to rapidly and slowly exchanging amide pools (Nfast, Nslow), measured at t = 0, were highly correlated with the extent of aggregation on storage as measured by SEC. In contrast, the extent of aggregation was weakly correlated with FTIR band intensity and peak position measured at t = 0. The results support the use of ssHDX-MS as a formulation screening tool in developing lyophilized protein drug products.
Protein drugs are often
formulated as lyophilized solids to preserve
their native structure and minimize the rate of degradation during
storage.[1] These lyophilized powders are
usually amorphous rather than crystalline, a fact that has been attributed
to the lyophilization process and the properties of the proteins themselves.
Though high resolution methods such as X-ray crystallography and NMR
spectroscopy can be used to study protein structure in solution and
in crystalline solids,[2−4] the methods for assessing protein structure in amorphous
solids are far more limited. Vibrational spectroscopy methods such
as Fourier transform infrared spectroscopy (FTIR)[5] and Raman spectroscopy[6] are
routinely used by pharmaceutical companies to probe protein secondary
structure in lyophilized powders, to assess the effects of formulation
additives (“excipients”), and to design formulations.
Such methods lack the structural resolution of X-ray crystallography
and NMR, however, and the data are only semiquantitative.Hydrogen–deuterium
exchange with mass spectrometric analysis
(HDX-MS) has been widely used to study protein structure, stability,
and dynamics in solution.[7,8] In HDX-MS, a protein
in aqueous solution is exposed to D2O and the rate and
extent of deuterium incorporation detected as a change in mass (m/z). Proteolytic digestion prior to MS
analysis allows exchange to be monitored with peptide-level resolution.[9−11] To preserve the sites of labeling during analysis, the reaction
is usually quenched by lowering pH and temperature to inhibit the
reverse reaction (“back exchange”). Together with rapid
sample analysis under refrigerated conditions, this typically allows
retention of label acquired by backbone amide groups,[12] so that the exposure of protein sequence to D2O can be mapped. In pharmaceutical development, HDX-MS has been used
to map the interactions between receptors and small molecule drugs,[13] to monitor conformational changes in protein
drugs mediated by post-translational modifications,[14] and to compare batch-to-batch variation in developing biosimilars.[15]To extend HDX-MS to lyophilized samples,
our group has developed
solid state hydrogen–deuterium exchange with mass spectrometric
analysis (ssHDX-MS) to measure protein structure and excipient interactions
in lyophilized powders with high resolution.[16−19] In ssHDX-MS, lyophilized samples
are exposed to D2O in the vapor phase at controlled relative
humidity (RH) and temperature. Samples are reconstituted under quenched
conditions and subjected to MS analysis with or without proteolytic
digestion. Our previous ssHDX-MS studies have shown that proteins
in lyophilized solids are protected from deuterium exchange in a manner
that depends on relative humidity, position in the protein sequence,
and the type and amount of excipient used.[17,20] For example, when compared to HDX in solution, HDX-MS of equinemyoglobin (Mb) colyophilized with sucrose showed greater protection
from exchange than Mb colyophilized with mannitol,[20] while samples colyophilized with guanidine hydrochloride
showed greater deuterium uptake than native Mb in aqueous solution.[19] When comparing different lyophilized formulations,
ssHDX-MS often shows differences not detected by FTIR.[20] This suggests that ssHDX-MS may be useful as
a screening tool to select formulations that best preserve protein
structure and so promote stability during storage. To date, however,
the relationship between the solid state structural information provided
by ssHDX-MS and protein stability in lyophilized powders has not been
explored.In the work reported here, we used ssHDX-MS and FTIR
to monitor
the effects of different excipients on the conformation of Mb in lyophilized
powders, and to relate these measures of structure to Mb aggregation
during 1 year (∼360 days) of storage of the lyophilized powder
under controlled conditions. The results demonstrate that quantitative
measures of deuterium exchange provided by ssHDX-MS are highly correlated
with aggregate formation during storage and provide a better indication
of the propensity for aggregation than secondary structure as measured
by FTIR.
Materials and Methods
Materials
Equinemyoglobin (Mb)
was purchased from
Sigma-Aldrich (St. Louis, MO). Mass spectrometry grade water, acetonitrile
(ACN), and formic acid (FA) were from ThermoFisher Scientific (Waltham,
MA). D2O was purchased from Cambridge Isotope Laboratories,
Inc. (Andover, MA). Pepsin from Sigma-Aldrich was immobilized on Poros
AL resin (Applied Biosystems, Foster City, CA) and packed into a high
performance liquid chromatography (HPLC) column (50 × 2.1 mm,
Grace Davison Discovery Sciences, Deerfield, IL). All other chemicals
used were at least reagent grade and used as received.
Sample Preparation
Mb was solubilized and dialyzed
thoroughly in 2.5 mM potassium phosphate buffer, pH 7.0 at 4 °C.
The dialyzed Mb stock solution (6.8 mg/mL) was used to prepare the
formulations shown in Table 1. The samples
were filtered using Millex-GV 0.22 μm PVDF filter (Millipore,
Billerica, MA) and filled as 2.2 mL into 8 mL glass vial (Nuova Ompi,
Padova, Italy) using a peristaltic pump (Flexicon PF6, Flexicon, Wilmington,
MA). The vials were loaded and freeze-dried in a Boc Edwards Lyophilizer
(Lyomax 0.4) (Boc Edwards, Tonawanda, NY). Lyophilization was initiated
by precooling the shelves to −2 °C, followed by freezing
at −40 °C. Primary drying was carried out under vacuum
(70 mTorr) at −35 °C for 75 h followed by secondary drying
at 25 °C for 12 h and 5 °C for 12 h. All vials were backfilled
with nitrogen prior to sealing. After lyophilization, the Mb formulations
were analyzed for any excipient and/or lyophilization induced changes
using dynamic light scattering (DLS), size exclusion chromatography
(SEC), FTIR, and ssHDX-MS, as described below. The lyophilized samples
were then placed on stability at 25 °C and 60% RH or 40 °C
and 75% RH over a period of 1 year. Samples were withdrawn at intervals
and analyzed for aggregate content by SEC and DLS as described below.
Table 1
Different Mb Formulations and the
Concentration of Ingredients Used
formulations
ingredients
MbA
MbB
MbC
MbD
MbE
myoglobin
(Mb)
1.7 mg/mL, 45% w/w
1.7 mg/mL, 45% w/w
1.7 mg/mL, 45% w/w
3.4 mg/mL, 90% w/w
0.4 mg/mL, 10% w/w
sucrose
1.7 mg/mL, 45% w/w
3.0 mg/mL, 80%
w/w
mannitol
1.7 mg/mL, 45% w/w
NaCl
1.7 mg/mL, 45% w/w
potassium phosphate (pH 7.0)
0.4 mg/mL, 10% w/w
0.4 mg/mL,
10% w/w
0.4 mg/mL, 10%
w/w
0.4 mg/mL, 10% w/w
0.4 mg/mL, 10% w/w
Solid State FTIR Spectroscopy
To evaluate excipient
and/or lyophilization induced secondary structural changes in Mb,
FTIR spectra were acquired for MbA, MbB, MbC, MbD, and MbE (Table 1) using a Tensor 37 FTIR spectrometer (Bruker Optics,
Billerica, MA). Approximately 2 mg of lyophilized protein was mounted
onto the ATR germanium crystal and the data collected with 128 scans
at a resolution of 4 cm–1. To avoid interference
from atmospheric water vapor, the system was continuously purged under
nitrogen. Background spectra collected under similar conditions were
subtracted from the raw spectra acquired for each sample. Data were
processed and analyzed using the OPUS software (version 6.5, Bruker
Optics). The raw spectra were first cut between 1720 and 1580 cm–1 to analyze the amide I band. Spectra were smoothed
using a nine-point Savitsky–Golay smoothing function, and baseline
correction was carried out using the rubberband correction method
with 64 baseline points. Finally, spectra were centered and min/max
normalized before second derivatization was carried out. The second
derivative spectra were obtained with an additional nine-point Savitsky–Golay
smoothing function.
Dynamic Vapor Sorption (DVS)
To
determine the rate
and extent of moisture sorption by Mb formulations during ssHDX-MS,
moisture sorption was measured using a gravimetric analyzer (Q5000SA;
TA Instruments, New Castle, DE). Approximately 3–4 mg of Mb
powder was loaded onto the platinum sample pan, and the samples were
heated to 85 °C at 0% RH for 10 min to remove any moisture present
before the start of the experiment. Samples were then equilibrated
at 5 °C, 0% RH and exposed to 33% RH for 24 h, with sorption
data collected at 4 s intervals.
ssHDX-MS for Intact Mb
To determine the rate and extent
of deuterium incorporation for intact (i.e., undigested) Mb, ssHDX-MS
was carried out at 5 °C by incubating the vials in a sealed desiccator
containing a saturated solution of MgCl2 in D2O (33% RH over D2O). Samples were removed at six different
time points over 240 h, and exchange was quenched by flash freezing
the vials in liquid nitrogen, which were then stored at −80
°C until analysis. Deuterium uptake by intact Mb was measured
using a high performance liquid chromatography mass spectrometer (LC/MS)
(1200 series LC, 6520 qTOF; Agilent Technologies, Santa Clara, CA)
equipped with a custom-built refrigeration unit which maintained the
column at ∼0 °C. The samples were quickly reconstituted
in chilled 0.2% formic acid (FA), and approximately 15 pmol of protein
was injected onto a protein microtrap (Michrom Bioresources, Inc.,
Auburn, CA). Samples were desalted for 1.7 min with 15% acetonitrile,
85% water, and 0.1% FA and eluted in 2.3 min using a gradient to 90%
acetonitrile, 10% water, and 0.1% FA. Mass spectra were obtained over
the m/z range 200–3200, and
the masses of both undeuterated and deuterated protein were obtained
by deconvoluting the spectra using MassHunter Workstation Software
(Version B.03.01, Agilent Technologies). To calculate the number of
deuterons incorporated in intact Mb, the mass of undeuterated Mb was
subtracted from the mass of deuterated Mb at each exchange time point.
Using GraphPad Prism software version 5 (San Diego, CA), deuteration
kinetic data for intact Mb in different formulations were fitted to
a biexponential model (eq 1) which assigns deuterons
to “fast” and “slow” exchanging pools,
as described previously.[21]Peak
width analysis for deuterated intact
Mb was carried out as described previously.[22]
ssHDX-MS for Mb at the Peptide Level
To determine the
distribution of deuterium incorporation along the Mb sequence, deuterated
Mb was subjected to proteolytic digestion with pepsin prior to MS
analysis. Exchange reactions were carried out as above, the quenched
sample was quickly reconstituted in chilled 0.2% formic acid (FA),
and approximately 15 pmol of protein was then injected into an immobilized
pepsin column. Online digestion was carried out for 2 min in water
containing 0.1% FA at a flow rate of 0.2 mL/min. The digested sample
was desalted in a peptide microtrap (Michrom Bioresources, Inc., Auburn,
CA) and eluted using a gradient of acetonitrile (10–60%) in
0.1% FA onto a reverse phase analytical column (Zorbax 300SB-C18;
Agilent Technologies) at 50 μL/min. The pepsin column, peptide
microtrap, and analytical column were located within the refrigeration
unit and connected through a two-position valve (EPC12CW, VICI Valco
Instruments Co., Inc., Houston, TX). The time elapsed between sample
reconstitution and MS analysis was 4–9 min. Mass spectra were
acquired over the m/z range 100–1700.
Peptides from an undeuterated Mb sample were also analyzed, and their
mass was measured by MS/MS analysis (CID fragmentation; MassHunter
Software; Agilent Technologies). Peptides indentified using undeuterated
Mb were mapped onto subsequent deuteration experiments using prototype
custom software, HDExaminer (Sierra Analytics, Modesto, CA), to obtain
the average number of deuterons exchanged for each of the pepsin digest
fragments. Kinetic data for deuteration of 13 nonredundant peptides
were fitted to a biexponential association model (eq 1) which accounts for deuterons exchanging at “fast”
and “slow” rates, as described above. Data from 48 h
ssHDX-MS samples were mapped onto the crystal structure of Mb (PDB
ID: 1WLA)[23] using PyMOL (PyMOL Molecular Graphics System,
Version 1.3, Schrodinger, LLC). Peak width analysis for the peptide
mass envelopes was carried out using HX-Express software as described
previously.[21,24,25]
Dynamic Light Scattering (DLS)
The formation of particles
in the stability samples was monitored using 90° DLS (Zetasizer
Nano ZS90, Malvern Instruments, Ltd., Westborough, MA). Approximately
1 mL of the reconstituted Mb sample was placed in a polystryrene cuvette
(VWR) and analyzed with a path length of 10 mm at 25 °C. Triplicate
samples for each formulation were recorded 3 times using an automatic
mode for the selection of best number of subruns. The z-average diameter (nm) was calculated from the correlation function
using the Dispersion Technology Software supplied with the instrument
(Version 4.20, Malvern, Westborough MA).
High Performance Size Exclusion
Chromatography (HP-SEC)
HP-SEC was used to assess the percentage
loss of monomeric Mb during
the stability study. An Agilent 1200 system with UV detection at 280
nm (Agilent Technologies, Palo Alto, CA) was used to monitor the loss
in monomeric protein. Vials containing lyophilized Mb for each formulation
were reconstituted with 2.2 mL of sterile distilled water; samples
in triplicate were centrifuged (Microfuge 22R refrigerated microcentrifuge,
VWR) at 14,000 rpm for 15 min to remove any insoluble protein aggregates.
25 μL aliquots were then injected onto a Tosoh TSKgel G3000SWxl
column (Tosoh Bioscience LLC, King of Prussia, PA; 3000 mm ×
7.8 mm) and eluted with buffer (50 mM potassium phosphate, 100 mM
NaCl, pH 7.5) at a flow rate of 0.5 mL/min. The percentage loss of
monomeric Mb was determined using the following equation (eq 2).
Results
Mb Secondary Structure by FTIR
Mb
secondary structure
in lyophilized samples was initially characterized using FTIR. Mb
is a globular protein with high (>80%) α-helix content. All
second derivative FTIR spectra showed a strong α-helix band
at ∼1654 cm–1. A decrease in band intensity
was observed for samples MbC and MbD, suggesting reduced α-helix
content for these formulations (Figure 1).
Figure 1
Overlay
of second derivative amide I FTIR spectra of Mb in formulations
MbA, MbB, MbC, MbD, and MbE.
Overlay
of second derivative amide I FTIR spectra of Mb in formulations
MbA, MbB, MbC, MbD, and MbE.
Moisture Sorption Kinetics by DVS
Before exchange can
occur in ssHDX-MS, D2O must be sorbed by the solid matrix
from the vapor phase and diffuse into the solid. The rate of moisture
sorption and diffusion thus may influence the rate of exchange. The
effect of hydration on HDX of Mb colyophilized with sucrose or mannitol
has been extensively characterized in our previous study.[20,21] The results showed that moisture sorption is complete in a period
of hours while HDX continues for days, indicating that, under conditions
comparable to those used here, HDX in lyophilized powders is not simply
a measure of moisture sorption.[21] In the
work reported here, the rate of moisture uptake was measured at 5
°C, 33% RH to confirm that the rate of water vapor sorption is
rapid relative to the deuterium exchange rate. The rate and extent
of moisture absorption differed among the formulations (Figure 2). The formulation with Mb alone (MbD) reached its
sorption maximum absorption in <1 h and sorbed more moisture (0.103
g water/g solid) than the other formulations. The formulations containing
sucrose (MbA, MbE) reached their sorption maxima in ∼20 h and
sorbed similar levels of moisture (0.085 and 0.083 g of water/g of
solid, respectively). Formulations containing mannitol (MbB) and NaCl
(MbC) sorbed the least moisture (0.053 and 0.064 g of water/g of solid,
respectively) but reached equilibrium in ∼2 h. Based on these
results, and since ssHDX occurs over hundreds of hours (see Figure 3 and Figure S2 in the Supporting
Information), it is unlikely that vapor sorption dominates
ssHDX kinetics, except at t < 24 h for samples
containing sucrose (MbA, MbE).
Figure 2
Moisture sorption kinetics for Mb formulations
MbA, MbB, MbC, MbD,
and MbE. Data were collected at 33% RH, 5 °C for 24 h.
Figure 3
(A) Overlay of deconvoluted mass spectra of
intact Mb from formulations
MbA, MbB, MbC, MbD, and MbE following 48 h of deuterium exchange.
UD: deconvoluted mass spectrum for undeuterated Mb. (B) Kinetics of
deuterium uptake for intact Mb in formulations MbA (closed circle),
MbB (closed triangle), MbC (open circle), MbD (open square), and MbE
(closed square). Plots of the time course of deuterium exchange were
fitted to an equation for two phase exponential association (GraphPad
Prism software version 5 (San Diego, CA)) (n = 3,
±SE).
Moisture sorption kinetics for Mb formulations
MbA, MbB, MbC, MbD,
and MbE. Data were collected at 33% RH, 5 °C for 24 h.(A) Overlay of deconvoluted mass spectra of
intact Mb from formulations
MbA, MbB, MbC, MbD, and MbE following 48 h of deuterium exchange.
UD: deconvoluted mass spectrum for undeuterated Mb. (B) Kinetics of
deuterium uptake for intact Mb in formulations MbA (closed circle),
MbB (closed triangle), MbC (open circle), MbD (open square), and MbE
(closed square). Plots of the time course of deuterium exchange were
fitted to an equation for two phase exponential association (GraphPad
Prism software version 5 (San Diego, CA)) (n = 3,
±SE).
Effect of Excipients on
Deuterium Uptake in Intact Mb
ssHDX-MS data were acquired
for the five formulations (Table 1) at six
different time points (1–240 h).
Overall, MbA and MbE showed less deuterium uptake than MbB, MbC, and
MbD (Table 2). Furthermore, MbE is less deuterated
than MbA, indicating that the greater sucrose content in MbE provides
greater protection from exchange. Formulations containing NaCl (MbC)
or without excipient (MbD) showed the greatest deuterium uptake at
all time points (Figure 3). The extent of deuterium
uptake at 48 h (Figure 3A and Table 2) was not simply related to the extent of water
vapor sorption at 24 h (Figure 2). For example,
MbC showed less moisture sorption than MbD but comparable deuterium
uptake. MbA and MbE (with sucrose) showed high vapor sorption yet
had the greatest protection from exchange, while MbB (with mannitol)
showed the lowest vapor sorption and an intermediate extent of exchange.
These results are consistent with our previous ssHDX-MS study of Mb
at 43% RH, in which Mb formulations with sucrose sorbed ∼25%
more moisture and showed 20% less deuteration than those containing
mannitol following 48 h of HDX.[21]
Table 2
Quantitative Measures of Deuterium
Uptake in Mb Formulations
peak
width (Da)
formulationa
deuterium uptake (%)b,c
Nfastb,d
Nslowb,d
Nfast/(Nfast + Nslow)
∼15% deuterationb,e
∼12.5% deuterationb,e
MbA
9.4 ± 0.1
19.6 ± 0.9
6.3 ± 0.4
0.76 ± 0.04
17.2 ± 0.3
15.4 ± 0.3
MbB
24.6 ± 0.2
39.8 ± 1.6
19.7 ± 1.4
0.67 ± 0.04
18.4 ± 0.1
15.8 ± 0.3
MbC
35.8 ± 0.2
36.0 ± 1.4
37.9 ± 1.1
0.49 ± 0.02
33.6 ± 1.1
MbD
32.7 ± 0.2
34.8 ± 0.9
32.7 ± 0.6
0.52 ± 0.01
31.1 ± 0.5
MbE
8.4 ± 0.1
14.6 ± 0.5
4.4 ± 0.3
0.77 ± 0.06
14.8 ± 0.2
See Table 1 for the composition.
Values obtained from three independent
ssHDX-MS experiments (mean ± SE).
Percent deuterium uptake relative
to theoretical maximum by intact Mb after 48 h of HDX at 5 °C,
33% RH.
Nfast and Nslow values were
determined by
nonlinear regression of ssHDX-MS kinetic data. Time course of deuterium
exchange for intact Mb was fitted to the two phase exponential association
model (eq 1).
Peak width was measured at 20% height
of the deconvoluted mass spectrum of intact Mb.
See Table 1 for the composition.Values obtained from three independent
ssHDX-MS experiments (mean ± SE).Percent deuterium uptake relative
to theoretical maximum by intact Mb after 48 h of HDX at 5 °C,
33% RH.Nfast and Nslow values were
determined by
nonlinear regression of ssHDX-MS kinetic data. Time course of deuterium
exchange for intact Mb was fitted to the two phase exponential association
model (eq 1).Peak width was measured at 20% height
of the deconvoluted mass spectrum of intact Mb.Kinetic plots of deuterium uptake
for intact Mb were fitted to
a biexponential model (Figure 3B). On average,
the Nfast and Nslow values for MbA and MbE were less than those for MbB, MbC, and MbD
(Table 2). Among the formulations, differences
in the Nslow values were larger than differences
in the Nfast values (Table 2). This suggests that greater Nslow values in MbB, MbC, and MbD may be due to the recruitment of amide
groups that do not exchange in MbA and MbE into the slowly exchanging
pool. The fraction of exchanging amide groups in the rapidly exchanging
pool is expressed in the ratio Nfast/(Nfast + Nslow) (Table 2), which provides another measure of the distribution
between the two pools.
Effect of Excipients on Deuterium Uptake
at the Peptide Level
A total of 41 fragments were identified;
from these, a nonredundant
set of 13 fragments covering 100% of the Mb sequence was selected
for analysis (Figure S1 in the Supporting Information). The average number of deuterons exchanged for each peptide was
calculated, and the results from 48 h samples were mapped onto the
crystal structure of Mb (PDB ID: 1WLA) (Figure 4). The
kinetics of deuterium uptake for the 13 nonredundant peptic fragments
showed biexponential behavior (Figure S2 in the Supporting Information), consistent with subpopulations of
amide groups undergoing “fast” and “slow”
exchange. The number of amides in the “fast” and “slow”
pools, Nfast and Nslow, varied with formulation and in different regions of the
Mb molecule (Figure 5). Overall, the Nfast and the Nslow values for most of the peptides in formulations MbB, MbC, and MbD
were greater than those in MbA and MbE, with the differences in the Nslow values somewhat greater than differences
in the Nfast values (Figure 5A,B).
Figure 4
Crystal structures of holo-Mb (PDB ID: 1WLA) showing the percent
deuterium uptake
for Mb in formulations MbA, MbB, MbC, MbD, and MbE following 48 h
of deuterium exchange. ssHDX-MS data from 13 nonredundant pepsin digest
fragments were mapped onto the structure. The heme group in holo-Mb
is shown in brown spheres; color coding for deuteration level is as
per legend key indicated.
Figure 5
Comparison of Nfast (A), Nslow (B), and Nfast/(Nfast + Nslow) (C)
values for Mb in formulations MbA, MbB, MbC, MbD, and MbE. Values
were obtained from nonlinear regression of ssHDX-MS kinetic data for
13 nonredundant peptic peptides (n = 3, ±SE).
Crystal structures of holo-Mb (PDB ID: 1WLA) showing the percent
deuterium uptake
for Mb in formulations MbA, MbB, MbC, MbD, and MbE following 48 h
of deuterium exchange. ssHDX-MS data from 13 nonredundant pepsin digest
fragments were mapped onto the structure. The heme group in holo-Mb
is shown in brown spheres; color coding for deuteration level is as
per legend key indicated.Comparison of Nfast (A), Nslow (B), and Nfast/(Nfast + Nslow) (C)
values for Mb in formulations MbA, MbB, MbC, MbD, and MbE. Values
were obtained from nonlinear regression of ssHDX-MS kinetic data for
13 nonredundant peptic peptides (n = 3, ±SE).The ssHDX-MS kinetic data also
differed in sucrose formulations
having different concentrations of excipient (MbA, MbE). Nfast values for peptides 1–29, 14–29, 28–32,
33–55, 70–105, 87–106, 106–137, 107–123,
and 138–153 in formulations MbA and MbE showed slight or no
differences, whereas Nslow values were
generally smaller in MbE than in MbA. Similarly, values of the Nfast/(Nfast + Nslow) ratio were greater for these peptides
in MbE (Figure 5C). For regions spanning residues,
1–7, 30–40, 56–69, and 119–148, the Nfast values for MbA were greater than for MbE,
and Nfast/(Nfast + Nslow) values were smaller. Together,
the results suggest that these regions in MbE are more rigid or folded
than in MbA.
Peak Width Determination for Deuterated Mb
In ssHDX-MS,
a comparison of peak widths at a similar level of deuteration is expected
to provide information on differences in the spatial and/or conformational
heterogeneity of proteins in solid samples.[20,21] For intact Mb, peak width steadily increased with time for formulations
MbB, MbC, and MbD but showed smaller increases in MbA and MbE (Figure 6A). To establish a level of deuterium uptake for
comparing different formulations, peak width was plotted against percentage
deuterium uptake (Figure 6B), and 15% deuterium
incorporation was selected for comparison. Since this value is greater
than the maximum deuterium uptake observed in MbE, it was omitted
from the comparison (Figure 6B). At ∼15%
deuterium uptake, MbC and MbD showed ∼2-fold greater peak width
than formulations MbA and MbB, and MbB showed slightly greater peak
width (∼1.2 Da) than MbA (Table 2).
Thus, peak width analysis in intact Mb suggests that protein in MbA
retained a greater degree of native structure and/or was more homogeneous
than in MbB, MbC, or MbD.
Figure 6
(A) Peak width broadening for intact deuterated
Mb as a function
of time. Peak width at 20% height of the deconvoluted mass spectrum
was measured for formulations MbA (closed circle), MbB (closed triangle),
MbC (open circle), MbD (open square), and MbE (closed square). (B)
Peak width broadening in formulations MbA, MbB, MbC, MbD, and MbE
with differing levels of deuterium uptake (n = 3,
±SE). (C) Comparison of peak width for 8 nonredundant peptic
peptides obtained from Mb in MbA, MbB, MbC, MbD, and MbE at similar
deuteration level. Peak with at 20% peak height was plotted for residues
1–29 at 15.1%, 28–32 at 6.2%, 30–40 at 6.1%,
33–55 at 17.2%, 56–69 at 7.9%, 70–105 at 9.3%,
106–137 at 10.0%, and 138–153 at 12.5% deuteration (n = 3, ±SE).
(A) Peak width broadening for intact deuterated
Mb as a function
of time. Peak width at 20% height of the deconvoluted mass spectrum
was measured for formulations MbA (closed circle), MbB (closed triangle),
MbC (open circle), MbD (open square), and MbE (closed square). (B)
Peak width broadening in formulations MbA, MbB, MbC, MbD, and MbE
with differing levels of deuterium uptake (n = 3,
±SE). (C) Comparison of peak width for 8 nonredundant peptic
peptides obtained from Mb in MbA, MbB, MbC, MbD, and MbE at similar
deuteration level. Peak with at 20% peak height was plotted for residues
1–29 at 15.1%, 28–32 at 6.2%, 30–40 at 6.1%,
33–55 at 17.2%, 56–69 at 7.9%, 70–105 at 9.3%,
106–137 at 10.0%, and 138–153 at 12.5% deuteration (n = 3, ±SE).Peak width analysis was also carried out for the peptic peptides
from Mb using HX-Express software. The eight nonredundant peptides
were analyzed for peak width to represent the distribution of conformations
of Mb within the solid matrix. The extent of deuteration of the eight
peptides of MbE at 240 h, relative to the theoretical maximum, were
as follows: residues 1–29, 15.1%; residues 28–32, 6.2%;
residues 30–40, 6.1%, residues 33–55, 17.2%; residues
56–69, 7.9%; residues 70–105, 9.3%; residues 106–137,
10.0%; and residues 138–153, 12.5%. Peak widths for the remaining
formulations were compared at an extent of deuteration equal to the
value for that peptide in MbE at 240 h. The increase in peak width
and its differences among formulations are region specific (Figure 6C and Figures S3 and S4 in the Supporting Information). For formulations MbC and MbD, the
N-terminal region (residues 1–29) showed a greater peak width
(∼2.5 Da) for formulations MbC and MbD than for the remaining
formulations. The region spanning residues 33–55 showed greater
peak widths (∼2.0 Da) for MbC and MbD (∼2.0 Da) and
for MbB (∼1.0 Da). Other regions (i.e., 56–69, 70–105,
106–137, and 138–153) also showed greater peak widths
for MbC and MbD, and to a lesser extent for MbB, though the magnitude
of the effect is not as large. These results are consistent with a
greater distribution of conformations in MbB, MbC, and MbD, particularly
in domains 1–29 and 33–55.
Effect of Excipients on
Mb Stability during Long-Term Storage
The stability of the
Mb formulations during long-term storage was
characterized using DLS and HP-SEC, which monitor subvisible particles
and loss of monomeric protein, respectively. For DLS analysis, the
lyophilized samples were reconstituted in sterile distilled water
and analyzed with a Zetasizer Nano ZS90 (Malvern Instruments, Ltd.,
Westborough, MA). The reconstituted lyophilized samples showed an
increase in particle size relative to the prelyophilized controls,
with the largest particle sizes observed in MbC and MbD (Figure S5
in the Supporting Information, t = 0). During storage at 25 and 40 °C, particle size
increased with time for formulations MbC and MbD at both temperatures.
MbA, MbB, and MbE showed a slight increase in particle size over time
(Figures 7A and 7B).
Figure 7
Mb aggregation
in lyophilized formulations during stability study,
as monitored using DLS and HP-SEC. The increase in particle size for
formulations stored at 25 °C (A) and 40 °C (B) and the percentage
loss of monomeric Mb for formulations stored at 25 °C (C) and
40 °C (D) were plotted against time (n = 3,
±SE). MbA (closed circle), MbB (closed triangle), MbC (open circle),
MbD (open square), and MbE (closed square).
Mb aggregation
in lyophilized formulations during stability study,
as monitored using DLS and HP-SEC. The increase in particle size for
formulations stored at 25 °C (A) and 40 °C (B) and the percentage
loss of monomeric Mb for formulations stored at 25 °C (C) and
40 °C (D) were plotted against time (n = 3,
±SE). MbA (closed circle), MbB (closed triangle), MbC (open circle),
MbD (open square), and MbE (closed square).The effects of excipients on lyophilization-induced aggregation
were also characterized using HP-SEC. Lyophilized samples were reconstituted
with sterile distilled water and subjected to HP-SEC, and the chromatographic
peak area was used to calculate the loss of monomeric Mb. At t = 0 (i.e., immediately after lyophilization and reconstitution),
the percent loss of Mb in formulations MbA, MbB, MbC, MbD, and MbE
was 1.3 ± 0.1, 0.8 ± 0.1, 4 ± 0.3, 1.4 ± 0.1,
and 1.3 ± 0.2%, respectively. To assess the effect of excipients
on Mb stability during storage, the lyophilized Mb formulations were
placed at 25 and 40 °C for a period of 360 days and evaluated
at regular intervals. The rate of loss of monomeric protein was greatest
for MbC at 25 °C and for MbB, MbC, and MbD at 40 °C (Figures 7C and 7D). At both temperatures,
the rate of aggregate formation was slowest in MbA and MbE and the
loss of monomeric Mb for these samples after 360 days was less than
4%.
Correlation of ssHDX-MS Results with Mb Stability on Storage
To evaluate ssHDX-MS as a potential screening tool for lyophilized
formulations, we correlated quantitative measures of deuterium exchange
in freshly lyophilized formulations (t = 0) to the
extent of aggregation during 6 months and 1 year of storage as measured
by HP-SEC. The quantitative measures of exchange were as follows:
(i) deuterium uptake in intact Mb after 48 h D2O exposure;
and (ii) Nfast/(Nfast + Nslow) values determined
by nonlinear regression of HDX kinetic data (eq 1) for intact Mb. The extent of aggregation was also correlated with
secondary structure in freshly lyophilized samples as measured by
α-helix band intensity and peak position in FTIR (Figures 8B1–8B4 and Figures
S6B1–S6B4 in the Supporting Information). For both 25 and 40 °C stability samples, the percent loss
of Mb monomer after 180 and 360 days increased monotonically with
the percent deuterium uptake as measured by ssHDX-MS at t = 0 (Figures 8A1 and 8A2 and Figures S6A1 and S6A2 in the Supporting
Information) (Table 3 and Table S1 in
the Supporting Information), and decreased
monotonically with Nfast/(Nfast + Nslow) (Figures 8A3 and 8A4 and Figures S6A3 and S6A4 in the Supporting Information) (Table 3 and Table S1 in the Supporting Information). In contrast, correlation of aggregation during storage with FTIR
measures of secondary structure was poor (Figures 8B1–8B4 and Figures S6B1–S6B4
in the Supporting Information) (Table 3 and Table S1 in the Supporting
Information).
Figure 8
Correlation of Mb aggregation during long-term storage
(at t = 360 days) with t = 0 ssHDX-MS
(A) and
FTIR (B) analysis. The percent loss of Mb monomer after 360 days of
storage at 25 and 40 °C as a function of percent deuterium uptake
(A1 and A2), Nfast/(Nfast + Nslow) (A3 and A4),
band intensity for α-helix (B1 and B2), and band position for
α-helix (B3 and B4) in formulations, MbA (closed circle), MbB
(closed triangle), MbC (open circle), MbD (open square), and MbE (closed
square) (n = 3, ±SE). The data were subjected
to linear regression to obtain slope, intercept, and R2 values (see Table 3).
Table 3
Parameters Obtained from the Correlation
of t = 0 ssHDX-MS and FTIR Results with the Percent
Loss Mb at t = 360 days
parametersb
figure no.a
slope
intercept
R2
8A1
0.52 ± 0.08
–2.58 ± 2.04
0.9308
8A2
1.44 ± 0.04
–5.80 ± 0.86
0.9983
8A3
–51.77 ± 3.82
42.05 ± 2.48
0.9839
8A4
–137.28 ± 17.14
114.11 ± 11.15
0.9553
8B1
2907.09 ± 1645.83
33.29 ± 14.01
0.5098
8B2
6385.00 ± 5141.23
79.78 ± 43.76
0.3396
8B3
–2.80 ± 2.40
4635.72 ± 4020.45
0.3063
8B4
–8.66 ± 6.06
14349.26 ± 10018.47
0.4052
Refer to Figure 8 for storage
conditions and variables used.
Parameters ± SE determined
by linear fit of values obtained from FTIR and HDX-MS experiments
at t = 0 against Mb aggregation at t = 360 days.
Correlation of Mb aggregation during long-term storage
(at t = 360 days) with t = 0 ssHDX-MS
(A) and
FTIR (B) analysis. The percent loss of Mb monomer after 360 days of
storage at 25 and 40 °C as a function of percent deuterium uptake
(A1 and A2), Nfast/(Nfast + Nslow) (A3 and A4),
band intensity for α-helix (B1 and B2), and band position for
α-helix (B3 and B4) in formulations, MbA (closed circle), MbB
(closed triangle), MbC (open circle), MbD (open square), and MbE (closed
square) (n = 3, ±SE). The data were subjected
to linear regression to obtain slope, intercept, and R2 values (see Table 3).Refer to Figure 8 for storage
conditions and variables used.Parameters ± SE determined
by linear fit of values obtained from FTIR and HDX-MS experiments
at t = 0 against Mb aggregation at t = 360 days.
Discussion
Lyophilization is often used in an attempt to inhibit aggregation
and other types of degradation in protein drug products. Though it
is often helpful in this regard, aggregates have nevertheless been
observed in lyophilized solids.[26−28] In general, the extent of aggregation
depends on the composition of the solid[29−31] and on lyophilization
process variables,[32−34] with optimal formulation and processing conditions
varying from protein to protein. To develop lyophilized protein drug
products in a rational way, the rates of degradation should be correlated
to measurable properties of the formulation. Identifying such properties
would enable a formulation to be designed to achieve
desired performance, rather than developed by trial-and-error in stability
studies requiring months or years to complete. To date, consensus
has not been reached on the properties that control degradation in
lyophilized solids, however. There have been a number of attempts
to correlate protein stability in the solid state with properties
such as glass transition temperature (Tg),[35] moisture content,[36] free volume measurement by gas pycnometry,[37] protein secondary structure as measured by FTIR,[35,38−41] and fast local dynamics measured using neutron scattering,[38,39] which have met with varying degrees of success. For example, though
FTIR measures of secondary structure correlated well with long-term
storage stability in some studies,[39,41] others have
reported a weak[35,38] or unsuccessful[40] correlation. A limitation common to these approaches is
that they rely on bulk properties of the matrix and/or population
averaged properties of protein molecule. Since protein instability
is driven by changes occurring at the molecular or functional group
scale, bulk methods may lack sufficient resolution to monitor the
relevant molecular environment. The spatial and dynamic heterogeneities
of amorphous solids[42−44] further complicate the picture.To address
the need for molecular-scale characterization of proteins
in lyophilized solids, our group has developed ssHDX-MS to assess
protein conformation and excipient interactions in the solid state
with peptide-level resolution.[16−21] In the current study, we used ssHDX-MS to correlate protein conformation
in solid samples with the extent of aggregation during long-term storage.
Five different Mb formulations were produced and characterized for
process- or formulation-induced structural changes prior to evaluating
long-term storage stability. The studies tested the hypothesis that
quantitative measures of protein conformation provided by ssHDX-MS
are correlated with the extent of Mb aggregation during storage, and
that the correlation is superior to those based on FTIR peak intensity
or position.Initial characterization of solid samples using
FTIR showed retention
of α-helix band intensity in formulations MbA, MbB, and MbE,
reflecting a high degree of native structure, while decreased band
intensity in MbC and MbD indicated structural perturbation. These
results suggest that formulations with sucrose (MbA and MbE) or mannitol
(MbB) are likely to be more stable. FTIR spectra did not reveal differences
among formulations MbA, MbB, and MbE at t = 0, however,
though the three formulations showed different levels of aggregation
on stability. In addition, the extent of aggregation was poorly correlated
to quantitative measures of secondary structure (i.e., peak intensity,
peak position) obtained from FTIR spectra (Figures 8B1–8B4).In contrast,
ssHDX-MS provided quantitative measures of protein
conformation that were highly correlated with the extent of aggregation
during storage. In ssHDX-MS analysis, Mb in formulations MbB, MbC,
and MbD showed greater deuterium uptake throughout the molecule than
formulations containing sucrose (MbA, MbE) (Figures 3–5). Formulations that were
indistinguishable by FTIR (MbA, MbB, MbE; Figure 1) showed measurable differences in the extent of ssHDX in
intact Mb after 48 h of D2O exposure (Figures 3A and 4), which were highly
correlated with aggregation during storage (Figures 8A1 and 8A2). Studies of ssHDX kinetics
allowed the number of amide groups in rapidly and slowly exchanging
pools to be quantified (Nfast, Nslow; Table 2). While
a definitive structural assignment of the Nfast and Nslow pools cannot be made, it is
reasonable to expect that the Nslow amide
groups correspond to regions that are protected from exchange, either
through folding of Mb or through interactions with the solid matrix.
In contrast, the Nfast amides are expected
to be present on the surface of protein molecule or to have limited
interaction with the matrix. The fraction in the rapidly exchanging
pool (Nfast/(Nfast + Nslow)) was also highly correlated
with the extent of aggregation on storage (Figures 8A3 and 8A4). Thus, the results of these
studies support the hypothesis that ssHDX-MS results are correlated
with the extent of Mb aggregation during storage, and that the correlation
is superior to those based on FTIR peak intensity or position. Previous
studies in solution have shown that cold-unfolded Mb retains a significant
amount of secondary structure and easily aggregates at moderate temperatures
through partially unfolded forms.[45] If
partial unfolding is also involved in Mb aggregation in the lyophilized
samples studied here, ssHDX-MS may be superior to FTIR as a measure
of aggregation potential because it can detect partial unfolding when
secondary structure is largely retained. However, it should be noted
that the results presented here cannot justify the poor correlation
observed in earlier FTIR studies,[35,38,40] since protein formulations and experimental conditions
used in those studies differ.With pepsin digestion, ssHDX-MS
provided additional, higher resolution
information on the effects of formulation on Mb conformation and stability.
Data from the digests show that portions of the Mb B-C helices (fragments
28–32, 30–40) and G helix (fragment 107–123)
are relatively unaffected by solid composition and show low deuterium
uptake in all five formulations (Figures 4, 5). In solution at low pH and temperature, Mb forms
an equilibrium molten globule involving helices A, G, and H, together
with part of the B helix; the molten globule is thought to be an intermediate
on the Mb folding pathway.[46] That the regions
most protected from exchange in lyophilized samples correspond to
the equilibrium molten globule suggests that this domain is folded
in all five lyophilized formulations, and that formulation primarily
affects folding in other Mb domains. Interestingly, residues 1–7
from the N-terminus (A helix) and residues 138–153 from the
C-terminus (H helix) are less protected from exchange in solid samples
than other helices in the equilibrium molten globule (Figures 4 and 5), though the reasons
for this are not clear. Whether the heme group is intact in the lyophilized
samples is also unclear, since it is not retained during LC/MS analysis
and patterns of exchange near the heme pocket are not conclusive (Figure 4). Nevertheless, the results demonstrate that high
resolution structural information can be obtained for proteins in
lyophilized solids using ssHDX-MS.Together, the results support
the use of ssHDX-MS as a screening
tool in developing stable lyophilized formulations of protein drugs.
The ssHDX-MS studies reported here were completed in 48 h; with sample
preparation and data analysis, the process required 7–10 days
in total. In room temperature (25 °C) stability studies, differences
among the formulations became clear only after 180 days (6 months)
of storage (Figure 7C,D). Accelerated (40 °C)
stability data at earlier time points were not indicative of the ultimate
rank-ordered performance of the formulations at room temperature (Figure 7C,D). Though Mb is a well-characterized protein,
ssHDX-MS can also be applied to new and incompletely characterized
proteins if the amino acid sequence is known. While we have used the
known X-ray crystal structure of Mb to map the sites of exchange in
the solid state, ssHDX-MS can be applied as a stand-alone method in
the absence of detailed structural information. In fact, the results
presented here demonstrate that storage stability is highly correlated
with the extent of HDX in the intact protein, data apart from other
structural characterization. The strong correlation of solid stability
with ssHDX-MS results reported here supports its wider adoption. However,
establishing the utility of ssHDX-MS as a formulation tool will ultimately
require that it be applied to many proteins and formulations.
Conclusions
ssHDX-MS provided quantitative measures of the conformation of
Mb in lyophilized solids which were highly correlated to aggregation
during 6 months and 1 year of storage in the solid state. In contrast,
spectral band intensity and position as measured by FTIR in lyophilized
solids was poorly correlated with aggregation during storage. The
results support the use of ssHDX-MS as a rapid screening tool to predict
the propensity for aggregation during storage and to discriminate
among candidate formulations.
Authors: David D Weis; Thomas E Wales; John R Engen; Matthew Hotchko; Lynn F Ten Eyck Journal: J Am Soc Mass Spectrom Date: 2006-07-27 Impact factor: 3.109
Authors: Bingquan Wang; Serguei Tchessalov; Marcus T Cicerone; Nicholas W Warne; Michael J Pikal Journal: J Pharm Sci Date: 2009-09 Impact factor: 3.534
Authors: Ehab M Moussa; Nathan E Wilson; Qi Tony Zhou; Satish K Singh; Sandeep Nema; Elizabeth M Topp Journal: Pharm Res Date: 2018-01-03 Impact factor: 4.200
Authors: Richard Y-C Huang; Roxana E Iacob; Stanley R Krystek; Mi Jin; Hui Wei; Li Tao; Tapan K Das; Adrienne A Tymiak; John R Engen; Guodong Chen Journal: J Am Soc Mass Spectrom Date: 2016-08-15 Impact factor: 3.109
Authors: Lavanya K Iyer; Gregory A Sacha; Balakrishnan S Moorthy; Steven L Nail; Elizabeth M Topp Journal: J Pharm Sci Date: 2016-04-01 Impact factor: 3.534
Authors: Candice J Crilly; Julia A Brom; Mark E Kowalewski; Samantha Piszkiewicz; Gary J Pielak Journal: Biochemistry Date: 2021-01-05 Impact factor: 3.162